Skip to main content
www.aace.comwww.aace.com
Home
About Us | Supporters | Contact Us
  • Endocrine Conditions
    • Adrenal
    • Diabetes
    • Obesity
    • Osteoporosis
    • Parathyroid
    • Pituitary
    • Thyroid
  • Healthy Lifestyles
    • Nutrition
    • Men's Health
    • Women's Health
    • Patient Stories
  • Resources
    • EmPower Magazine
      • Linka
      • Linkb
      • Linkc
    • EmPower Videos
    • Diabetes Navigator
    • Diabetes Emergency Plan
    • Blood Sugar Basics
    • The Type 2 Talk
    • Find an Endocrinologist
    • Thyroid Awareness resources
  • Store
  • Get Involved
>

Thyroid Cancer

Hashimoto's Thyroiditis

  • About
  • Thyroid Conditions
  • Neck Check
  • Nodules & Cancer
  • Treatment
  • Hyperthyriodism
  • Hypothyroidism
  • Hashimoto's
  • Graves' Disease
  • Pregnancy and Thyroid

Hashimoto’s Thyroiditis

Hashimoto’s thyroiditis (also called autoimmune or chronic lymphocytic thyroiditis) is the most common thyroid disease in the United States. It is an inherited condition that affects over 10 million Americans and is about seven times more common in women than in men. Hashimoto’s thyroiditis is characterized by the production of immune cells and autoantibodies by the body’s immune system, which can damage thyroid cells and compromise their ability to make thyroid hormone. Hypothyroidism occurs if the amount of thyroid hormone, which can be produced, is not enough for the body’s needs. The thyroid gland may also enlarge, forming a goiter.

Signs & Symptoms
Hashimoto’s thyroiditis may not cause symptoms for many years and remain undiagnosed until an enlarged thyroid gland or abnormal blood tests are discovered as part of a routine examination. When symptoms do develop, they are either related to local pressure effects in the neck caused by the goiter itself, or to the low levels of thyroid hormone. The first sign of this disease may be painless swelling in the lower front of the neck. This enlargement may eventually become easily visible. It may be associated with an uncomfortable pressure sensation in the lower neck. This pressure on surrounding structures may cause additional symptoms, including difficulty swallowing.
Although many of the features associated with thyroid hormone deficiency occur commonly in patients without thyroid disease, patients with Hashimoto’s thyroiditis who develop hypothyroidism are more likely to experience the following:
  • Fatigue
  • Drowsiness
  • Forgetfulness
  • Difficulty with learning
  • Dry, brittle hair and nails
  • Dry, itchy skin
  • Puffy face
  • Constipation
  • Sore muscles
  • Weight gain
  • Heavy menstrual flow
  • Increased frequency of miscarriages
  • Increased sensitivity to many medications

The thyroid enlargement and/or hypothyroidism caused by Hashimoto’s thyroiditis progresses in many patients, causing a slow worsening of symptoms. Therefore, patients with either of these findings should be recognized and adequately treated with thyroid hormone. Optimal treatment with thyroid hormone will eliminate any symptoms due to thyroid hormone deficiency, usually prevent further thyroid enlargement, and may sometimes cause shrinkage of an enlarged thyroid gland.

hide

Causes
Hashimoto’s thyroiditis results from a malfunction in the immune system. When working properly, the immune system is designed to protect the body against invaders, such as bacteria, viruses, and other foreign substances. The immune system of someone with Hashimoto’s thyroiditis mistakenly recognizes normal thyroid cells as foreign tissue, and it produces antibodies that may destroy these cells. Although various environmental factors have been studied, none have been positively proven to be the cause of Hashimoto’s thyroiditis.

hide

Diagnosis
A physician experienced in the diagnosis and treatment of thyroid disease can detect a goiter due to Hashimoto’s thyroiditis by performing a physical examination and can recognize hypothyroidism by identifying characteristic symptoms, finding typical physical signs, and doing appropriate laboratory tests.
You can perform a simple “Neck Check”. Click here to learn how.
  • Antithyroid Antibodies – Increased antithyroid antibodies provide the most specific laboratory evidence of Hashimoto’s thyroiditis, but they are not present in all cases.
  • TSH (Thyroid — Stimulating Hormone or Thyrotropin) Test –Increased TSH level in the blood is the most accurate indicator of hypothyroidism. TSH is produced by another gland, the pituitary, which is located behind the nose at the base of the brain. The level of TSH rises dramatically when the thyroid gland even slightly underproduces thyroid hormone. So in patients with normal pituitary function, a normal level of TSH reliably excludes hypothyroidism.
  • Other Tests:
    • An estimate of free thyroxine - the active portion of all of the thyroxine circulating in the blood. A low level of free thyroxine is consistent with thyroid hormone deficiency. However, free thyroxine values in the “normal range” may actually represent thyroid hormone deficiency in a particular patient, since a high level of TSH stimulation may keep the free thyroxine levels “within normal limits” for many years.
    • Fine-needle aspiration of the thyroid- usually not necessary for most patients with Hashimoto’s thyroiditis, but a good way to diagnose difficult cases and a necessary procedure if a thyroid nodule is also present.

hide

Treatment
For patients with thyroid enlargement (goiter) or hypothyroidism, thyroid hormone therapy is clearly needed, since proper dosage corrects any symptoms due to thyroid hormone deficiency and may decrease the goiter’s size. Treatment generally consists of taking a single daily tablet of levothyroxine. Older patients who may have underlying heart disease are usually started on a low dose and gradually increased, while younger, healthy patients can be started on full replacement doses at once. While you may improve in many ways within a week, the full impact of thyroid medicine may take quite some time. For example, skin changes may take up to 3-6 months to resolve. Because of the generally permanent and often progressive nature of Hashimoto’s thyroiditis, it is usually necessary to treat it throughout one’s lifetime and to realize that medicine dose requirements may have to be adjusted from time to time.

Optimal adjustment of thyroid hormone dosage, guided by laboratory tests rather than symptoms alone, is critical, since the body is very sensitive to even small changes in thyroid hormone levels. Levothyroxine tablets come in 12 different strengths, and it is essential to take them in a consistent manner every day. If the dose is not adequate, the thyroid gland may continue to enlarge and symptoms of hypothyroidism will persist. This may be associated with increased serum cholesterol levels, possibly increasing the risk for atherosclerosis and heart disease. If the dose is too strong, it can cause symptoms of hyperthyroidism, creating excessive strain on the heart and an increased risk of developing osteoporosis.
hide

Click to Print This Page
Tags: 
Hasimoto's Thyroiditis
Thyroid
Thyroid Cancer
Hyperthyroidisim
Tweet
  • Read more about Hashimoto's Thyroiditis

Graves’ Disease

  • About
  • Thyroid Conditions
  • Neck Check
  • Nodules & Cancer
  • Treatment
  • Hyperthyriodism
  • Hypothyroidism
  • Hashimoto's
  • Graves' Disease
  • Pregnancy and Thyroid

Graves’ Disease

Graves’ disease (named after Irish physician Robert Graves) is an autoimmune disorder that frequently results in thyroid enlargement and hyperthyroidism. In some patients, swelling of the muscles and other tissues around the eyes may develop, causing eye prominence, discomfort or double vision. Like other autoimmune diseases, this condition tends to affect multiple family members. It is much more common in women than in men and tends to occur in younger patients.

Click to Print This Page
Tags: 
Hyperthyroidisim
Hasimoto's Thyroiditis
Thyroid
Thyroid Cancer
Tweet
  • Read more about Graves’ Disease

ThyCa: Thyroid Cancer Survivors’ Association (www.thyca.org) Marks 15th Year Serving Patients, Families, Professionals, and Public

ThyCa: Thyroid Cancer Survivors’ Association (www.thyca.org) Marks 15th Year Serving Patients, Families, Professionals, and Public
Support Services, Education, Conferences, Outreach, and Thyroid Cancer Research Grants
by Gary Bloom, Roselle Kovitz, Cherry Wunderlich

Thyroid cancer, which occurs in people of all ages from young children though seniors, is now diagnosed in about 37,000 people in the United States each year. While the majority of cases are treatable, with an excellent prognosis, some will not be so fortunate. For everyone, a diagnosis of thyroid cancer is life changing, regardless of its severity.

ThyCa: Thyroid Cancer Survivors’ Association provides a broad range of free support services, publications, and events to help thyroid cancer patients, their families, caregivers, and friends.

ThyCa’s free services and resources include 11 e-mail support groups and a Facebook presence serving over 10,500 participants. The Person-to-Person Network matches people seeking support with a volunteer with the same diagnosis. The Toll-Free Number Team and E-Mail Team provide one-to-one support. More than 80 local support groups in 35 U.S. states, as well as Canada, Costa Rica, and Philippines, help survivors and caregivers meet others in their communities.

ThyCa’s Web site (www.thyca.org) provides more than 650 pages of comprehensive, medically reviewed thyroid cancer information, plus connections to ThyCa services, events, and other organizations, including AACE. ThyCa receives ongoing input from its 33-member Medical Advisory Council and over two dozen additional thyroid cancer specialists.

Free downloadable publications on the Web site include the widely used ThyCa Low-Iodine Cookbook, available in English, French, and Spanish with guidelines from ThyCa medical advisors and researchers, and over 250 delicious recipes. It helps people with papillary and follicular thyroid cancer prepare for radioiodine scans or treatments.

ThyCa mails out free patient information packets and free pediatric backpacks. The free online newsletter ThyCa News Notes goes to more than 15,000 people each month. ThyCa also sponsors Thyroid Cancer Awareness Month in September, and year-round awareness campaigns.

Free bulk materials for physicians, hospitals, and community groups include the Thyroid Cancer Awareness Brochure featuring actress Catherine Bell, a thyroid cancer survivor; a fine needle aspiration booklet in English and Spanish, plastic wallet cards, and “Do you have thyroid cancer” brochures.

Free regional workshops feature physician speakers and will take place on Saturday, April 17, 2010, in Kansas City, Missouri; on Saturday, May 22, in Towson, Maryland; and on Saturday, May 29, in St. John’s, Newfoundland, Canada.

The annual 3-day Thyroid Cancer Survivors’ Conference grows each year, with more than 450 thyroid cancer survivors, caregivers, and health care professionals gathering last October in Boston, Massachusetts, from around the United States, Brazil, Canada, Puerto Rico, and United Kingdom. The 100-plus sessions included nearly 50 physician-led sessions with more than 25 physician speakers.

The 13th International Thyroid Cancer Survivors’ Conference will take place on October 15-17, 2010, in Dallas, Texas. The conference has a nominal registration fee of $50, or $30 for registrants/ guests, with scholarships for the registration fee available on request.

ThyCa raises funds for thyroid cancer research to find cures for all thyroid cancer, recognizing that many have lost their lives to thyroid cancer. ThyCa awarded the first patient-funded thyroid cancer research grant in 2003 and has awarded grants every year since. It will award two new research grants in 2010. One project will focus on papillary, follicular, and anaplastic, and the other on medullary thyroid cancer.

ThyCa grants are available to researchers worldwide. Recipients have included researchers at Cochin Institut, Harvard Medical School, Johns Hopkins University School of Medicine, Ohio State University and Medical University of Gdansk, Memorial Sloan-Kettering Cancer Center, Rush-Presbyterian-St. Luke's Medical Center, University Hospital Basel, University Hospital Duesseldorf, University of California Los Angeles/Veterans Affairs West Los Angeles Health Care System, and University of Texas M.D. Anderson Cancer Center.

We thank the American Association of Clinical Endocrinologists for the opportunity to introduce ThyCa’s services and resources. We invite all AACE members to tell your patients about ThyCa’s Web site, free services and resources. We greatly appreciate the fine work that endocrinologists do in support of patient care and well-being, and in research toward cures for all thyroid cancer.

For information or to request free materials, e-mail thyca@thyca.org, call 1-877-588-7904, fax to 1-630-604-6078, write ThyCa: Thyroid Cancer Survivors’ Association, Inc., PO Box 1545, New York, NY 10159-1545, or visit www.thyca.org.

Click to Print This Page
Tags: 
Thyroid
Thyroid Cancer
THYCA
Tweet
  • Read more about ThyCa: Thyroid Cancer Survivors’ Association (www.thyca.org) Marks 15th Year Serving Patients, Families, Professionals, and Public

management of patients with thyroid nodules and differentiated thyroid cancer: A summary

American Thyroid Association revised guidelines for the
Management of Patients with Thyroid nodules and Differentiated Thyroid Cancer: A Summary
by Dr. David S. Cooper

Chair, American Thyroid Association Thyroid Nodule and Thyroid Cancer Guidelines Task Force

In november, the American Thyroid Association published a revision of its "Guidelines for the Management of Thyroid Nodules and Thyroid Cancer" in its journal, Thyroid. The guidelines are available free to the public at the American Thyroid Association web site (www.thyroid.org). The revised guidelines represent two years of work and modernize the original "thyroid nodule and thyroid cancer guidelines" that were published in 2006. The impetus for the revision was the large number of new clinical research findings that had been published on this topic over the last three years. Also, thyroid cancer is an important topic because of its increasing incidence in the United States and around the world. Furthermore, thyroid nodules, or “lumps on the thyroid,” continue to be diagnosed with great frequency, possibly because of the widespread use of various imaging procedures (CAT scans, MRIs, carotid ultrasound) that detect thyroid nodules "incidentally" or "by accident" with increasing frequency. The guidelines are "evidence-based" which means that the various research studies that were reviewed by the task force were rated according to whether the study provided "good" or "fair" evidence that a particular test or treatment would be effective. For those interventions where there is very little good research, the task force made recommendations based on “expert opinion.”
Diagnosing Thyroid Cancer

For the management of thyroid nodules (See Dr. Duick’s piece and the thyroid nodules information), the guidelines focus on how physicians should evaluate patients with thyroid nodules using laboratory tests, thyroid ultrasound, and other imaging tools such as thyroid scans. It is recommended that all patients with one or more suspected thyroid nodules have thyroid ultrasound performed for three reasons: to precisely measure the nodule’s size; to see whether other nodules may be present within the thyroid that can't be felt; and, importantly, to look at the ultrasound appearance of the nodule or nodules, since it is now known that the ultrasound characteristics of a nodule is very helpful in establishing the likelihood it may be benign or malignant. The guidelines then make recommendations, based on the size of the nodule, the ultrasound appearance of the nodule, and other criteria, for which patients should have their nodule biopsied or aspirated, using a fine needle under ultrasound guidance. The guideline task force believes that the revised guidelines may lead to fewer biopsies being performed in the future, since the appearance of the nodule on ultrasound rather than its size should play a greater role in deciding whether a biopsy is performed.

Treating Thyroid Cancer

The extent of surgery that is necessary for patients with thyroid cancer is another major topic discussed in the revised guidelines. The guidelines review criteria to help decide which patients require a total thyroidectomy versus a simple lobectomy removing only half of the thyroid, and which patients should have removal of potentially involved lymph nodes in the neck near the thyroid at the time of surgery. Following surgery, many patients will receive radioactive iodine to destroy the small amount of thyroid tissue that was left behind, known as remnant thyroid tissue. The new guidelines review which patients should receive this form of therapy, and which patients can be followed without additional treatment. Recent studies suggest that radioactive iodine therapy is not necessary in many low risk patients, and the guidelines task force believes that the new recommendations will lead to fewer patients receiving radioactive iodine in the future.

The guidelines also discuss how patients with thyroid cancer should be treated with thyroid hormone following thyroidectomy. Many patients benefit from relatively high doses of thyroid hormone, which will lower their serum TSH levels. The purpose of this relates to the fact that TSH, a hormone that normally appears in the blood stream, can be a growth factor for thyroid cancer. On the other hand, too much thyroid hormone may have side effects, especially in elderly patients (e.g., osteoporosis in postmenopausal women, heart rhythm disturbances, symptoms of nervousness and anxiety). The guidelines discuss how to maximize the beneficial effects of thyroid hormone and to minimize the potential complications of thyroid hormone therapy.

Following Patients with Thyroid Cancer

The new guidelines review the use of serum thyroglobulin measurements in thyroid cancer patients. Thyroglobulin is a thyroid protein made by either normal thyroid tissue or thyroid cancer. Therefore, after all thyroid tissue is removed or destroyed by surgery and radioactive iodine therapy, serum thyroglobulin serves as an important tumor marker that is used to monitor patients to detect persistent or recurrent disease. The interpretation of thyroglobulin levels requires a certain degree of expertise on the part of the physician. The revised guidelines also discuss the management of patients with advanced thyroid cancer, and recommend that radioactive iodine therapy be used in some patients, while other patients may be suitable candidates for newer therapies that are still not yet approved for thyroid cancer management by the U.S. Food and Drug Administration (For more information, please see section by Steven Sherman). On the other hand, even patients with widespread disease may do well without any treatment at all, since thyroid cancer often progresses very slowly and may have few symptoms.

Future Thyroid Cancer Research

Finally, the guidelines present a number of areas for future research that the task force felt were especially important. These include more information on how to manage widespread metastatic disease using newer chemotherapy agents, better understanding of the long-term outcome of patients with very minimal disease that is detectable only because their serum thyroglobulin levels are slightly elevated, and better ways of measuring serum thyroglobulin in patients who have anti-thyroglobulin antibodies. This last issue is a particularly vexing one for approximately 20% of thyroid cancer patients, in whom serum thyroglobulin cannot be measured accurately.

The revised "thyroid nodule and thyroid cancer guidelines" is a "living document", and will be revised again in another 2-3 years. The field is moving rapidly, and the American Thyroid Association is dedicated to providing clinicians with the best and most up to date evidence to help them manage their patients who have thyroid nodules and thyroid cancer.

David S. Cooper, MD, is a graduate of Johns Hopkins University. He received his medical degree from Tufts University School of Medicine where he was elected to Alpha Omega Alpha, and completed his Internal Medicine residency at Barnes Hospital/Washington University School of Medicine. He completed his Endocrinology Fellowship training at the Massachusetts General Hospital/Harvard Medical School. He is Professor of Medicine and International Health at the Johns Hopkins University School of Medicine and the Bloomberg Johns Hopkins School of Public Health, and Director of the Johns Hopkins Thyroid Clinic. He is a Contributing Editor of the Journal of the American Medical Association (JAMA), and is the Deputy Editor of the Journal of Clinical Endocrinology and Metabolism. He also serves as Editor-in-Chief for Endocrinology at Up-to-Date. He is the current Chair of the Subspecialty Board for Endocrinology, Diabetes, and Metabolism of the American Board of Internal Medicine. Dr. Cooper is the past Treasurer and the past President of the American Thyroid Association, and is also the recipient of the American Thyroid Association’s Distinguished Service Award.

Click to Print This Page
Tags: 
Thyroid Cancer
Thyroid
Research
Guidelines
Tweet
  • Read more about management of patients with thyroid nodules and differentiated thyroid cancer: A summary

A dentist appointment I’ll never forget

A Dentist Appointment I’ll Never Forget: A Patient Story
By Karen A. Avitabile

My dentist saved my life. Yes, my dentist.

During a routine six-month cleaning, my dentist checked my neck and under my tongue. This was not foreign to me. He explained years earlier cancers of the throat, tongue and jaw were on the rise, and it is his job to make sure everything is normal with each patient.

While feeling my neck, he noticed a lump on the right side. “It may be a swollen gland, but if it doesn’t go away in a few weeks visit your medical doctor,” he said.

Nearing age 40, I led a busy life. In addition to my full-time job as a travel editor with AAA, I had just returned to college to pursue a second degree and volunteered in my community. I exercised regularly and watched my diet.

I never had a swollen gland, but I didn’t think it was something that was going to slow me down – I couldn’t see the lump, it didn’t bother me and I felt perfectly fine.

A week later, I visited my gynecologist for my annual exam. I told him what the dentist said and asked him to check my neck for a swollen gland.

“Swollen gland?” he said. “That’s your thyroid and you should see your regular doctor.”

OK, maybe there was something wrong with my thyroid, I thought. So if I have to take medication, it wasn’t the end of the world.

I went to my general practitioner the next day. He scheduled blood work and an ultrasound to “see what’s going on.”
Results of the blood work didn’t show any problems with my thyroid but the ultrasound showed a three-centimeter lump leaning on the right side of my thyroid. I was referred to a surgeon to discuss options.

“You’ve got this large lump which will never go away,” the surgeon said. “In fact, it will probably get bigger. We can biopsy it to ensure it is not cancer, or just keep an eye on it. It’s your call.”

“Is a biopsy going to tell us 100 percent if I have cancer?” I asked.

“Nope. Ninety-five percent,” he said.

That 5 percent gray area was all I needed to hear to make my decision -- I wanted to have the lump removed. This also meant removing the right side of the thyroid. In my mind, there was no way around it. I wasn’t willing to take a chance with my life.

Prior to the surgery, my father was diagnosed with Lou Gehrig’s Disease, a progressive neurodegenerative disease which causes patients to become paralyzed and leads to death. He was one in 50,000 people annually diagnosed with this debilitating disease.

I remember thinking those were crazy odds and certainly didn’t think I would be one of the over 35,000 people diagnosed with thyroid cancer each year.

Some family and friends thought I was crazy for going through with the surgery. “Why don’t you just get it biopsied each year? Why would you want to remove most of a vital organ if you don’t have to?” some asked.

The answer was simple – because I refused to gamble my life away.
The morning of the surgery, the doctor explained that it would take about 90 minutes to remove the right lobe of my thyroid. He added that they would be testing the right lobe for cancer. He asked if he could remove the whole thyroid if that was the case. I granted my permission.

The clock on the wall was the first thing I saw in the recovery room when I woke up. I quickly did the math. More than three hours had passed. I knew this was a bad sign.

My fears were confirmed when my doctor entered the room.

“You had cancer,” he said. “We had to remove your entire thyroid.”

When I arrived in my hospital room, I tried to compose myself before facing my family. “In a few minutes,” I repeated to a nurse who kept coming in to tell me my family was waiting to see me.

Like me, my family knew something was wrong based on the length of time the surgery took. My doctor gave them the news before they came in to see me.

No one, especially me, could believe this had happened to me.

The next morning, the nurse came in to give me my first dose of levothyroxine – a thyroid replacement medication that I would have to take daily for the rest of my life.

I was not looking forward to what lie ahead, who would? In addition to my daily medication, I would have to undergo radioactive iodine therapy, ultrasounds and ongoing monitoring.

After a few days, the lab tests confirmed I had papillary thyroid cancer, one of the more common types, and I was expected to make a full recovery.
Within two months, I underwent radioactive iodine treatment – to ensure any remaining thyroid cells in my body would be destroyed – and another ultrasound. All tests came back negative for additional cancer.

Four years later, I remain cancer-free. I see my endocrinologist every three months, have an annual ultrasound examination and ingest a small amount of radioactive iodine each year as a precaution. My endocrinologist monitors my TSH (thyroid stimulating hormone) levels. If they are either too high or too low, he may choose to increase or decrease my dose of levothyroxine. He also organizes my ultrasounds and radioactive iodine treatments.

Other than that, I’m back to living the life I’m used to. I graduated from college for the second time in May 2009, still volunteer in the community, exercise and continue to travel the globe as part of my work at AAA. Of course, my levothyroxine is the first thing I pack now.

When you first hear the word “cancer,” the natural response is fear. As I have come to learn firsthand, however, thyroid cancer is very treatable and manageable.

I may be one in 25,000 people to be diagnosed with thyroid cancer, but I still consider myself lucky in many regards.

And I thank my dentist every time I see him.

Editor's note
We were delighted to receive Ms. Avitabile’s unsolicited contribution to our magazine. Previously, endocrinologists belonging to AACE submitted all magazine pieces featuring patients.

Ms. A’s decision to undergo surgery regardless of the result of a biopsy based on her wishes to eliminate uncertainty is a well-accepted basis for having surgery. Although a fine needle aspiration may be inconclusive, it is standard practice to do one before surgery. In some cases, in addition to establishing whether or not to remove both sides of the thyroid, it could lead to further preoperative evaluation in order to determine whether even more extensive surgery such as lymph node removal will be required (see sections on thyroid cancer). While her family and friends advised her to “get it biopsied each year”, yearly biopsies are not necessary when a nodule appears to be benign and is not growing. Lastly, although yearly ultrasounds are routinely done for several years after papillary thyroid cancer is diagnosed, most cases do not require yearly radioactive iodine imaging.

Click to Print This Page
Tags: 
Inspiring Stories
Thyroid Dysfunction
Thyroid Cancer
Neck
Dentist
Tweet
  • Read more about A dentist appointment I’ll never forget

Thyroid Cancer and ChemoTherapy

Thyroid Cancer and ChemoTherapy
By dr. steven i. sherman

In 2009, at least 36,000 persons in the United States were diagnosed with one of the various forms of thyroid cancer, a number that has been increasing at a surprisingly rapid rate (See Dr. Cooper’s piece on pages 8-9 and our handout on pages 19-20). Fortunately, most of these persons will do very well, and live long enough to die from something other than their thyroid cancer. Surgery to remove the cancerous thyroid gland, often including neck lymph nodes as well, is the primary treatment used. For the most common thyroid cancers (papillary or follicular cancer), many patients are also treated with radioactive iodine and high doses of thyroid hormone. Some individuals may experience cancer reoccurrence, and often additional surgery and/or radioactive iodine therapies are capable of adequately treating these patients.

Some patients with thyroid cancer, however, develop serious problems, including cancer that metastasizes (or spreads) outside the neck to the lungs, bones, or other organs. More than 1,500 persons die each year because of complications of thyroid cancer. For these patients, traditional therapies are often ineffective. Surgery, radioactive iodine, and radiation treatments can occasionally reduce symptoms or treat problems that emerge because of progressing cancer. But, these treatments rarely cure metastatic thyroid cancer. Like other malignancies, chemotherapies have been tried. Drugs that are used for other forms of cancer, like doxorubicin (Adriamycin®) or cisplatinum (Cisplatin®), were studied in the 1970s and 1980s, with little evidence of benefit. Only about one out of five patients with metastatic thyroid cancer that did not respond to prior therapy saw significant tumor shrinkage when treated with one or both of these chemotherapies, and cure was rare. Side effects were considerable, including reduced blood counts, increased risk for infections, hair loss, nausea, and vomiting. As a result, traditional chemotherapies have only been recommended for patients with very advanced disease as a “last ditch” effort.

“As drug companies have recently created many new drugs that attack angiogenesis or the abnormal cancer proteins, new opportunities have emerged for testing novel treatments for advanced thyroid cancer.”

As disappointing as these poor results from chemotherapy were, even more frustrating was the lack of success in developing more effective or safer treatments. Between 1975 and 2000, few clinical trials testing new therapies for thyroid cancer were started, and they usually failed to attract enough participants to test adequately new treatments. Further, pharmaceutical companies were reluctant to devote sufficient resources to support new drug development for the disease, given the small numbers of patients who needed help and the failure of earlier studies.

The past five years have seen a remarkable turnaround in these trends. First, scientists have discovered many key steps involved in the development of thyroid cancers that provide potential “targets” for therapy. For example, many cancers require the creation of new blood vessels (called “angiogenesis”) for them to grow larger than a few millimeters or to invade and spread to other parts of the body. Angiogenesis appears to be as critical for thyroid cancers as for more common malignancies like colon or lung cancer. Additionally, genetic mutations in thyroid DNA that cause most thyroid cancers have been discovered. These abnormal genes lead to production of abnormal proteins in the tumor cell that promote the growth of the cancer, but these abnormal proteins can also be targeted by drugs as a way to treat the disease. As drug companies have recently created many new drugs that attack angiogenesis or the abnormal cancer proteins, new opportunities have emerged for testing novel treatments for advanced thyroid cancer. Second, patients and their physicians have become more aware of the availability of clinical trials testing new therapies. Thyroid cancer patients are now being referred by their physicians to participate in all phases of trials of promising drugs, with considerable success.

An example of this new approach was the early testing of the drug motesanib, an inhibitor of angiogenesis. Nearly one in ten of the cancer patients in the earliest trials testing this drug were patients with advanced thyroid cancer, and several of them had good responses to the treatment. An international clinical trial was then performed to test the drug specifically in patients with growing papillary or follicular thyroid cancers that would not respond to more conventional treatments like radioactive iodine. Unlike previous attempts at clinical trials, this one succeeded, filling up with more patients than were actually needed months ahead of schedule. More importantly, nearly three-quarters of patients with previously growing metastatic thyroid cancers either experienced significant tumor shrinkage or at least saw their tumors stop growing, often for many months. Other drugs have also been tested this way in the past several years as well. Evidence is mounting that the drug sorafenib (Nexavar®) might similarly stop the growth of metastatic thyroid cancer by blocking angiogenesis as well as by affecting one of the mutated proteins found in papillary thyroid cancer (called BRAF).

Much research is now ongoing to try to find better treatments for advanced thyroid cancers. At The University of Texas M. D. Anderson Cancer Center (www.mdanderson.org), where I work, we are studying several different approaches and new drugs. Our thyroid cancer research team involves endocrinologists, surgeons, and medical oncologists including those who specialize in the very earliest of drug studies (called “phase I trials”). Patients can find information about our studies as well as those being done elsewhere through the web site www.clinicaltrials.gov.

Side effects from these treatments definitely occur, and patients need to be aware that problems like high blood pressure, diarrhea, fatigue, and bad skin rashes frequently occur with these new drugs. In some cases, skin cancers are appearing while patients are treated with certain drugs. Therefore, patients need to be carefully selected who truly need these treatments, and they and their physicians must be on the lookout for development of side effects that themselves could require treatment. But, for many of our patients, as long as the benefits of the new chemotherapies outweigh the side effects, we carefully push forward with their treatments.

With these advances, organizations such as the American Thyroid Association and the National Comprehensive Cancer Network now recommend that patients with progressing or symptomatic metastatic thyroid cancer, not responding to more traditional therapies like surgery or radioiodine, should be referred to participate in clinical trials of new or experimental drug treatments. Such research is absolutely necessary if we are to develop improved therapies that can cure metastatic thyroid cancer. However, for those patients who cannot or choose not to enter a clinical trial, treatment with angiogenesis inhibitors like sorafenib which are available for the treatment of other cancers can now be considered as a potential helpful option.

Steven I. Sherman, MD, is the Naguib Samaan Distinguished Professor in Endocrinology, the Chair of the Department of Endocrine Neoplasia and Hormonal Disorders, and Medical Director of the Endocrine Multidisciplinary Center at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. After graduating from Harvard College magna cum laude in Biochemistry and Molecular Biology, Dr. Sherman earned his medical degree from the Johns Hopkins School of Medicine in Baltimore, Maryland. He stayed at Johns Hopkins for his internship and residency in internal medicine, and clinical fellowship in endocrinology and metabolism. He joined the faculty at Johns Hopkins upon completion of his training, and in 1993 was recruited to the M.D. Anderson Cancer Center.
Specializing in the management of patients with advanced endocrine malignancies, Dr. Sherman is Director of the National Thyroid Cancer Treatment Cooperative Study Group and serves as Treasurer of the International Thyroid Oncology Group. He has led numerous phase II clinical trials evaluating novel therapies for metastatic thyroid cancer. He is author or co-author of more than 80 peer-reviewed journal articles, including New England Journal of Medicine, Annals of Internal Medicine, Lancet, Journal of Clinical Endocrinology and Metabolism, and Journal of Clinical Oncology.

Click to Print This Page
Tags: 
Thyroid
Thyroid Cancer
Thyroid Carcinoma
Chemotherapy
Tweet
  • Read more about Thyroid Cancer and ChemoTherapy

Battling Thyroid Cancer “dee”

Battling Thyroid Cancer “DEE”

By Greg Willis

Talk about driven. Dee is the very definition of the word. She’s a hard-working, intelligent woman, thriving in the hustle and bustle of downtown Manhattan. Dee works as a consultant in corporate communications, and hasn’t slowed down much in the last ten years - despite battling thyroid cancer.

Ten years ago, she was an undergraduate about to attend Columbia University in New York. Before beginning the fall semester, she scheduled an appointment with the family doctor for an annual physical. Despite feeling fine, the doctor noticed something odd: A lump in her throat.

“The lump was quite insignificant,” Dee said. “In fact, it could only really be seen from the side. It came as a surprise that this could potentially be something worth worrying about.”

After she discovered the lump, Dee underwent surgery to have the “cyst” removed. During surgery, cancer was discovered.

“Looking back on it now, I should’ve requested a biopsy immediately after they noticed the lump in my throat,” she said. “But I was 24, and being a potential candidate for cancer never even crossed my mind for a second. It was surprising.”

Dee then underwent a complete thyroidectomy to remove all of the cancerous areas around her thyroid one month later. Her thyroidectomy was performed at Brigham and Women’s Hospital in Boston.

Since the diagnosis 10 years ago, she has undergone six additional surgeries related to the thyroid cancer. During that time, she continued her studies at Columbia University and then went on to get her Masters at the London School of Economics and Political Science. “It certainly made for hectic semesters,” Dee joked.

“My family was very supportive of my choices during that time,” she said. “They encouraged me to do whatever I wanted, but to make certain that I was receiving good care.”

And essentially that’s what she has continued to do. Her endocrinologist of 10 years, Dr. Jeffrey Garber of Harvard Vanguard Medical Associates, reports that although the cancer is not completely cured, she’s in great health and continues to live a normal and active lifestyle.

“I’ve been insistent that this won’t stop me,” Dee said. “And I haven’t let it.”

"Looking back on it now, I should've ordered a biopsy immediately after they noticed the lump in my throat," she said. "But I was 24, and being a potential candidate for cancer never even crossed my mind for a second. it was suprising."

Click to Print This Page
Tags: 
Thyroid
Thyroid Dysfunction
Thyroid Cancer
Thyroid Carcinoma
Inspiring Stories
Tweet
  • Read more about Battling Thyroid Cancer “dee”

Thyroid Cancer

  • About
  • Thyroid Conditions
  • Neck Check
  • Nodules & Cancer
  • Treatment
  • Thyroid Nodules
  • Thyroid Cancer

What is Thyroid Cancer?

The thyroid gland is located in the lower front of the neck, above the collarbones, and below the voice box (larynx). Thyroid cancer (carcinoma) usually appears as a painless lump in this area. In most cases, the lump is only on one side, and the results of thyroid function tests (blood tests) are usually normal.

There are four main types of thyroid cancer (papillary, follicular, medullary and anaplastic). Since the vast majority are either papillary or follicular, and these are the only two types treatable with radioiodine, this section will focus on these two types.

Signs & Symptoms
Many patients with thyroid cancer have no symptoms whatsoever, and are found by chance to have a lump in the thyroid gland during a routine physical exam, or an imaging study of the neck done for unrelated reasons such as a carotid ultrasound, CT or MRI scan of the spine or chest. Other patients with thyroid cancer become aware of a gradually enlarging lump in the front portion of the neck, which usually moves with swallowing. Occasionally, the lump may cause a feeling of pressure. Obviously, finding a lump in the neck should be brought to the attention of your physician, even in the absence of other symptoms.
hide
Types of Thyroid Cancer
Most common types of thyroid cancer are “sporadic” or isolated, and not inherited.
  • Most common types of thyroid cancer are “sporadic” or isolated, and not inherited. However, an uncommon type of thyroid cancer, medullary, which makes up about 5% of all thyroid cancers, can be familial, or run in families. When medullary cancer is inherited as a familial disease, it can be detected by a genetic blood test. Unless the disease is inherited, your children will not be affected.
  • Papillary thyroid cancer is the most common type of thyroid cancer, accounting for 70-80% of call cases. It is most commonly diagnosed in women 30-40 years old and most frequently spreads to cervical (neck) lymph nodes.
  • Follicular thyroid cancer is the second most common type of thyroid cancer, accounting for 10-15% of cases. Although it usually does not spread, when it does it goes to the lungs and bones through the bloodstream.
  • Anaplastic thyroid cancer accounts for less than 5% of thyroid cancer patients. It is the most aggressive form of thyroid cancer and treatment is rarely effective.

Because the most common thyroid cancers, papillary and follicular, tend to grow slowly, usually do not spread beyond the neck, and respond to treatment, most patients with thyroid cancers have excellent prognoses. For example, the 20-year survival of the most common type, papillary thyroid cancer, is almost 95%.

The estimated number of new thyroid cancer patients for 2011 was 48,020 (incidence rate). This number is due to a continuing upward trend in the number of newly diagnosed thyroid cancer patients of 2% each year for more than 15 years! This represents an alarming and rapid percentage increase for any form of cancer, especially since most all other cancers are either stable or declining in their incidence rates. Fortunately, virtually the entire rate of increasing thyroid cancer patients annually is due to newly diagnosed papillary cancer (rather than other types of more aggressive thyroid cancer). The exact cause (or causes) is not clear; but, this rise in the incidence of papillary thyroid cancer has been attributed to better and earlier diagnostic imaging with ultrasound. However, other background environmental causes are difficult to exclude and there are continuing efforts to analyze this incidence trend.

hide

Causes of Thyroid cancer
As with many types of cancer, the specific reason for developing thyroid cancer remains a mystery in the vast majority of patients. Some major risk factors are:
  • External radiation to the head or neck, especially during childhood
  • Genetic predisposition (the influence of heredity), particularly for the medullary type of thyroid cancer

hide

Diagnosis of Thyroid cancer
First, your physician takes a detailed history and performs a careful physical examination, especially of the thyroid gland. The best diagnostic approach for a specific patient will be determined by your physician after careful consideration of all the facts. The tests available to your physician for evaluation of the thyroid lump include, but are not limited to, the following:
  • Fine-needle aspiration biopsy– this is usually done first and, if positive, significantly reduces the need for more elaborate and expensive testing
  • Ultrasonography – this may be required for guidance of the fine needle biopsy if the nodule is difficult to feel
  • Thyroid scan – this can be done to see if the mass is capable of concentrating radioiodine, particularly in those patients with low TSH levels, who are likely to have hot nodules, which are almost always benign.
  • Blood studies

Read more about these procedures in the Thyroid Nodules section.
hide

Treatment of Thyroid cancer
The great majority of patients with thyroid cancer have a disease that can be successfully treated. In order to ensure your chances for successful treatment, it is important to receive treatment and follow-up care from those with a great deal of experience in the diagnosis and treatment of thyroid cancer. This is usually an endocrinologist, a doctor who specializes in hormone-related disorders.

If the diagnosis of thyroid cancer is certain or highly likely, the usual approach is to remove both sides of the thyroid gland. If the diagnosis of thyroid cancer is much less certain or cannot be made during surgery, only the side of the thyroid containing the lump may be removed. If cancer is subsequently confirmed, further consultation with the endocrinologist is appropriate. Additional surgery to remove the remaining tissue and radioactive iodine treatment are usually recommended in order to destroy any remaining malignant thyroid cells and to reduce the risk of recurrence of this disease.

You may be thinking, shouldn’t I be seeing an oncologist. The answer is not usually. The endocrinologist is the physician who deals primarily with the diagnosis, treatment, and follow-up of most patients with thyroid cancer. When standard therapy fails to control the progression of thyroid cancer and chemotherapy is being considered, then consultation with an oncologist is appropriate.
hide

Treatment Questions
What treatment will I require?
Treatment depends on the type and extent of cancer. Treatment options include surgery, radioactive iodine, external radiation (see below), and chemotherapy. All patients require thyroid surgery and many receive radioiodine after surgery. External radiation is sometimes necessary when tumors cannot be removed surgically or eliminated by radioactive iodine.

What kind of surgery?
Removal of part or all of the thyroid gland (thyroidectomy) is the first step in management. Lymph nodes with cancer in them are also removed. A surgeon who has experience with thyroid cancer is the best choice for performing your surgery.

Will I require radiation? What type?
Conventional radiation therapy, the type that is generally used for cancer is not used very often to treat thyroid cancer. It is reserved to treat thyroid cancer that cannot be removed surgically or eliminated with radioactive iodine. Fortunately, it is only required to treat a small minority of thyroid cancer cases. This type of radiation treatment is often referred to as external radiation therapy because the source of the radiation comes from outside the body.
Most often patients with thyroid cancer who require radiation treatment receive radioactive iodine. This type of radiation works internally once it enters your body. It is administered by either swallowing a capsule or drinking a radioactive liquid; containing a radioactive form of iodine.

hide

Pregnancy and thyroid cancer
Radioactive iodine treatment should never be given to a pregnant or nursing woman. Small amounts of radioactive iodine will also be excreted in breast milk. Since radioiodine could permanently damage the infant’s thyroid, breast-feeding is not allowed. If radioiodine is inadvertently administered to a woman who is subsequently discovered to be pregnant, the advisability of terminating the pregnancy should be discussed with the patient’s obstetrician and endocrinologist. Therefore, prior to administering diagnostic or therapeutic radioiodine treatment, pregnancy testing is mandatory whenever pregnancy is possible.

After radioiodine therapy, thyroid medication (levothyroxine) should be started and dosed to replace the function of the thyroid and to decrease the likelihood of cancer recurrence. Periodic monitoring is supervised by the endocrinologist, and may include ultrasound examinations, radioiodine body scans, and periodic testing of a blood protein called thyroglobulin, which is found in normal thyroid cells but can also be produced by thyroid cancer cells.

The optimal frequency of further monitoring studies to be certain that the cancer has not recurred will be determined by your physician. Fortunately, most cases of thyroid cancer have a very good prognosis when diagnosed early and treated by a physician who is familiar with its management.
Learn more and pregnancy and thyroid here.

hide

Tags: 
Thyroid
Thyroid Cancer
Thyroid Dysfunction
Thyroid Awareness
Tweet
  • Read more about Thyroid Cancer

Hypothyroidism

  • About
  • Thyroid Conditions
  • Neck Check
  • Nodules & Cancer
  • Treatment
  • Hyperthyriodism
  • Hypothyroidism
  • Hashimoto's
  • Graves' Disease
  • Pregnancy and Thyroid

Hypothyroidism

An underactive thyroid, or hypothyroidism, occurs when the thyroid gland produces less than the normal amount of thyroid hormone. The result is the “slowing down” of many bodily functions. Although hypothyroidism may be temporary, it usually is a permanent condition. Of the nearly 30 million people estimated to be suffering from thyroid dysfunction, most have hypothyroidism.

Signs & Symptoms
In its earliest stage, hypothyroidism may cause few symptoms, since the body has the ability to partially compensate for a failing thyroid gland by increasing the stimulation to it, much like pressing down on the accelerator when climbing a hill to keep the car going the same speed. As thyroid hormone production decreases and the body’s metabolism slows, a variety of features may result.
  • Pervasive fatigue
  • Drowsiness
  • Forgetfulness
  • Difficulty with learning
  • Dry, brittle hair and nails
  • Dry, itchy skin
  • Puffy face
  • Constipation
  • Sore muscles
  • Weight gain and fluid retention
  • Heavy and/or irregular menstrual flow
  • Increased frequency of miscarriages
  • Increased sensitivity to many medications

hide

Causes
  • Autoimmune Thyroiditis: The body’s immune system may produce a reaction in the thyroid gland that results in hypothyroidism and, most often, a goiter (enlargement of the thyroid). Other autoimmune diseases may be associated with this disorder, and additional family members may also be affected.
  • Radioactive Iodine Treatment: Hypothyroidism frequently develops as a desired therapeutic goal after the use of radioactive iodine treatment for hyperthyroidism.
  • Thyroid Operation: Hypothyroidism may be related to surgery on the thyroid gland, especially if most of the thyroid has been removed.
  • Medications: Lithium, high doses of iodine, and amiodarone (Cordarone, Pacerone) can cause hypothyroidism.
  • Subacute Thyroiditis: This condition may follow a viral infection and is characterized by painful thyroid gland enlargement and inflammation, which results in the release of large amounts of thyroid hormone into the blood. Fortunately, this condition usually resolves spontaneously. The thyroid usually heals itself over several months, but often not before a temporary period of hypothyroidism occurs.
  • Postpartum Thyroiditis: Five percent to ten percent of women develop mild to moderate hyperthyroidism within several months of giving birth. Hyperthyroidism in this condition usually lasts for approximately one to two months. It is often followed by several months of hypothyroidism, but most women will eventually recover normal thyroid function. In some cases, however, the thyroid gland does not heal, so the hypothyroidism becomes permanent and requires lifelong thyroid hormone replacement. This condition may occur again with subsequent pregnancies.
  • Silent Thyroiditis: Transient (temporary) hyperthyroidism can be caused by silent thyroiditis, a condition which appears to be the same as postpartum thyroiditis but not related to pregnancy. It is not accompanied by a painful thyroid gland.
  • Congenital Hypothyroidism: An infant may be born with an inadequate amount of thyroid tissue or an enzyme defect that does not allow normal thyroid hormone production. If this condition is not treated promptly, physical stunting and/or mental damage (cretinism) may develop.
  • Central or Pituitary Hypothyroidism: TSH is produced by the pituitary gland, which is located behind the nose at the base of the brain. Any destructive disease of the pituitary gland or hypothalamus which sits just above the pituitary gland may cause damage to the cells that secrete Thyroid-Stimulating Hormone (TSH), which stimulates the thyroid to produce normal amounts of thyroid hormone. This is a very rare cause of hypothyroidism.

hide

Diagnosis
Characteristic symptoms and physical signs, which can be detected by a physician, can signal hypothyroidism. However, the condition may develop so slowly that many patients do not realize that their body has changed, so it is critically important to perform diagnostic laboratory tests to confirm the diagnosis and to determine the cause of hypothyroidism.
You can perform a simple “Neck Check”. Click here to learn how.
  • TSH (Thyroid – Stimulating Hormone or Thyrotropin) Test: An increased TSH level in the blood is the most accurate indicator of primary (non-pituitary) hypothyroidism. Production of this pituitary hormone is increased when the thyroid gland even slightly underproduces thyroid hormone.
  • Other Tests:
    • Estimates of free thyroxine - the active thyroid hormone in the blood. It is important to note that there is a range of free thyroxine levels in the blood of normal people, similar to the range for height, and that a value of free thyroxine that is “within normal limits” for the general population may not be appropriate for a particular individual.
    • Thyroid autoantibodies - indicates the likelihood of auto-immune thyroiditis being the cause of hypothyroidism.

A primary care physician may make the diagnosis of hypothyroidism, but assistance is often needed from an endocrinologist, a physician who is a specialist in thyroid diseases.

hide

Treatment
Hypothyroidism is generally treated with a single daily dose of levothyroxine, given as a tablet. An experienced physician can prescribe the correct form and dosage to return the thyroid balance to normal. Older patients who may have underlying heart disease are usually started at a low dose and gradually increased while younger healthy patients can be started on full replacement doses at once. Thyroid hormone acts very slowly in some parts of the body, so it may take several months after treatment for some features to improve.

Since most cases of hypothyroidism are permanent and often progressive, it is usually necessary to treat this condition throughout one’s lifetime. Periodic monitoring of TSH levels and clinical status are necessary to ensure that the proper dose is being given, since medication doses may have to be adjusted from time to time. Optimal adjustment of thyroid hormone dosage is critical, since the body is very sensitive to even small changes in thyroid hormone levels.

Levothyroxine tablets come in 12 different strengths, and it is essential to take them in a consistent manner every day. A dose of thyroid hormone that is too low may fail to prevent enlargement of the thyroid gland, allow symptoms of hypothyroidism to persist, and be associated with increased serum cholesterol levels, which may increase the risk for atherosclerosis and heart disease. A dose that is too high can cause symptoms of hyperthyroidism, create excessive strain on the heart, and lead to an increased risk of developing osteoporosis.

It is extremely important that women planning to become pregnant are kept well adjusted, since hypothyroidism can affect the development of the baby. During pregnancy, thyroid hormone replacement requirements often change, so more frequent monitoring is necessary. Various medications and supplements (particularly iron) may affect the absorption of thyroid hormone; therefore, the levels may need more frequent monitoring during illness or change in medication and supplements.

Thyroid hormone is critical for normal brain development in babies. Infants requiring thyroid hormone therapy should NOT be treated with purchased liquid suspensions, since the active hormone may deteriorate once dissolved and the baby could receive less thyroid hormone than necessary. Instead, infants with hypothyroidism should receive their thyroid hormone by crushing a single tablet daily of the correct dose and suspending it in one teaspoon of liquid and administering it properly.
Appropriate management of hypothyroidism requires continued care by a physician experienced in the treatment of this condition.

hide

Click to Print This Page
Tags: 
Hypothyroidisim
Hyperthyroidisim
Thyroid Cancer
Thyroid
Tweet
  • Read more about Hypothyroidism
Subscribe to RSS - Thyroid Cancer
SITEMAP
  • About
  • Supporters
  • Contact Us
ENDOCRINE CONDITIONS
  • Adrenal
  • Diabetes
  • Obesity
  • Osteoporosis
  • Parathyroid
  • Pituitary
  • Thyroid
RESOURCES
  • EmPower Magazine
  • Diabetes Navigator
  • Diabetes Disaster Plan
  • Blood Sugar Basics
  • The Type 2 Talk
  • Find an Endocrinologist
  • HEALTHY LIFESTYLES

  • Nutrition
  • Men's Health
  • Women's Health

VOL4 ISSUE2
Defying the Odds:Phil Southerland’s Story of Living with Type 1 Diabetes and Founding Team Type 1